Literature DB >> 15557616

A heterologous DNA priming-Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and Apa antigens improves protection against tuberculosis in mice.

Jose C Ferraz1, Evangelos Stavropoulos, Min Yang, Steve Coade, Clara Espitia, Douglas B Lowrie, M Joseph Colston, Ricardo E Tascon.   

Abstract

Tuberculosis is responsible for >2 million deaths a year, and the number of new cases is rising worldwide. DNA vaccination combined with Mycobacterium bovis bacillus Calmette Guerin (BCG) represents a potential strategy for prevention of this disease. Here, we used a heterologous prime-boost immunization approach using a combination of DNA plasmids and BCG in order to improve the efficacy of vaccination against Mycobacterium tuberculosis infection in mice. As model antigens, we selected the M. tuberculosis Apa (for alanine-proline-rich antigen) and the immunodominant Hsp65 and Hsp70 mycobacterial antigens combined with BCG. We demonstrated that animals injected with a combination of DNA vectors expressing these antigens, when boosted with BCG, showed increased specific antimycobacterial immune responses compared to animals vaccinated with BCG alone. More importantly, the protection achieved with this regimen was also significantly better than with BCG alone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15557616      PMCID: PMC529122          DOI: 10.1128/IAI.72.12.6945-6950.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis.

Authors:  C G Feng; U Palendira; C Demangel; J M Spratt; A S Malin; W J Britton
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

2.  Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model.

Authors:  M A Horwitz; G Harth; B J Dillon; S Maslesa-Galic'
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

Review 3.  How can immunology contribute to the control of tuberculosis?

Authors:  S H Kaufmann
Journal:  Nat Rev Immunol       Date:  2001-10       Impact factor: 53.106

Review 4.  Tuberculosis vaccine development: recent progress.

Authors:  I M Orme; D N McMurray; J T Belisle
Journal:  Trends Microbiol       Date:  2001-03       Impact factor: 17.079

5.  Decreased capacity of recombinant 45/47-kDa molecules (Apa) of Mycobacterium tuberculosis to stimulate T lymphocyte responses related to changes in their mannosylation pattern.

Authors:  C Horn; A Namane; P Pescher; M Rivière; F Romain; G Puzo; O Bârzu; G Marchal
Journal:  J Biol Chem       Date:  1999-11-05       Impact factor: 5.157

Review 6.  Variation in protection by BCG: implications of and for heterologous immunity.

Authors:  P E Fine
Journal:  Lancet       Date:  1995-11-18       Impact factor: 79.321

7.  Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines.

Authors:  P J Murray; A Aldovini; R A Young
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-23       Impact factor: 11.205

8.  Antigenic and structural similarities between Mycobacterium tuberculosis 50- to 55-kilodalton and Mycobacterium bovis BCG 45- to 47-kilodalton antigens.

Authors:  C Espitia; R Espinosa; R Saavedra; R Mancilla; F Romain; A Laqueyrerie; C Moreno
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

9.  Identification of a Mycobacterium bovis BCG 45/47-kilodalton antigen complex, an immunodominant target for antibody response after immunization with living bacteria.

Authors:  F Romain; A Laqueyrerie; P Militzer; P Pescher; P Chavarot; M Lagranderie; G Auregan; M Gheorghiu; G Marchal
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

10.  Inhibition of adjuvant arthritis by a DNA vaccine encoding human heat shock protein 60.

Authors:  Francisco J Quintana; Pnina Carmi; Felix Mor; Irun R Cohen
Journal:  J Immunol       Date:  2002-09-15       Impact factor: 5.422

View more
  29 in total

1.  Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens.

Authors:  Lan Wu; Wing-Pui Kong; Gary J Nabel
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

2.  Brugia malayi: comparison of protective immune responses induced by Bm-alt-2 DNA, recombinant Bm-ALT-2 protein and prime-boost vaccine regimens in a jird model.

Authors:  Sivasakthivel Thirugnanam; Pandurangan Pandiaraja; Kalyanasundaram Ramaswamy; Vadivel Murugan; Munirathinam Gnanasekar; Krithika Nandakumar; Maryada Venkata Rami Reddy; Perumal Kaliraj
Journal:  Exp Parasitol       Date:  2007-03-06       Impact factor: 2.011

3.  Identification of surrogates and correlates of protection in protective immunity against Mycobacterium bovis infection induced in neonatal calves by vaccination with M. bovis BCG Pasteur and M. bovis BCG Danish.

Authors:  J C Hope; M L Thom; M McAulay; E Mead; H M Vordermeier; D Clifford; R G Hewinson; B Villarreal-Ramos
Journal:  Clin Vaccine Immunol       Date:  2011-01-12

Review 4.  Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis.

Authors:  Michael J Brennan; Bartholt Clagett; Hillary Fitzgerald; Vicki Chen; Ann Williams; Angelo A Izzo; Lewellys F Barker
Journal:  Vaccine       Date:  2012-03-03       Impact factor: 3.641

5.  DNA vaccine with α-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells.

Authors:  Daejin Kim; Chien-Fu Hung; T-C Wu; Yeong-Min Park
Journal:  Vaccine       Date:  2010-09-17       Impact factor: 3.641

6.  A single dose of a DNA vaccine encoding apa coencapsulated with 6,6'-trehalose dimycolate in microspheres confers long-term protection against tuberculosis in Mycobacterium bovis BCG-primed mice.

Authors:  Dyego Carlétti; Denise Morais da Fonseca; Ana Flávia Gembre; Ana Paula Masson; Lívia Weijenborg Campos; Luciana C C Leite; Andréa Rodrigues Pires; Joseli Lannes-Vieira; Célio Lopes Silva; Vânia Luiza Deperon Bonato; Cynthia Horn
Journal:  Clin Vaccine Immunol       Date:  2013-06-05

7.  The order of prime-boost vaccination of neonatal calves with Mycobacterium bovis BCG and a DNA vaccine encoding mycobacterial proteins Hsp65, Hsp70, and Apa is not critical for enhancing protection against bovine tuberculosis.

Authors:  Margot A Skinner; D Neil Wedlock; Geoffrey W de Lisle; Michèle M Cooke; Ricardo E Tascon; Jose C Ferraz; Douglas B Lowrie; H Martin Vordermeier; R Glyn Hewinson; Bryce M Buddle
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

8.  Assessment of immune response to repeat stimulation with BCG vaccine using in vitro PBMC model.

Authors:  Rajpal S Kashyap; Aliabbas A Husain; Shweta H Morey; Milind S Panchbhai; Poonam S Deshpande; Hemant J Purohit; Girdhar M Taori; Hatim F Daginawala
Journal:  J Immune Based Ther Vaccines       Date:  2010-05-28

9.  CpG-modified plasmid DNA encoding flagellin improves immunogenicity and provides protection against Burkholderia pseudomallei infection in BALB/c mice.

Authors:  Yao-Shen Chen; Yu-Shan Hsiao; Hsi-Hsun Lin; Yin Liu; Ya-Lei Chen
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

10.  DNA vaccination by electroporation and boosting with recombinant proteins enhances the efficacy of DNA vaccines for Schistosomiasis japonica.

Authors:  Yang Dai; Yinchang Zhu; Donald A Harn; Xiaoting Wang; Jianxia Tang; Song Zhao; Fei Lu; Xiaohong Guan
Journal:  Clin Vaccine Immunol       Date:  2009-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.